Skip to main content
Premium Trial:

Request an Annual Quote

WellGen Raises $3M in Series B Financing

NEW YORK, Feb. 16 (GenomeWeb News) - WellGen closed a $3-million Series B funding round, the company said today.


The capital will be used to begin clinical studies in humans under its obesity and inflammation programs, said the company in a statement.


The lead investor was Amphion Innovations. The company said investors included "new and existing shareholders."


Further details were not provided.


New Brunswick, NJ- based WellGen develops technologies to screen the effect of food on the expression of genes associated with human disease.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.